BMY:NYE-Bristol-Myers Squibb Company

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing

USD 49.13

Change

-0.59 (-1.19)%

Market Cap

USD 93.95B

Volume

0.01B

Analyst Target

USD 59.44
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bristol-Myers Squibb Co is a biopharmaceutical company. It discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
SCYB Schwab Strategic Trust

-0.11 (-0.21%)

N/A

ETFs Containing BMY

MEDX Horizon Kinetics Medical .. 5.62 % 0.00 %

-0.13 (0.05%)

USD 0.75B
FHI-B:CA CI Health Care Giants Cov.. 5.10 % 0.00 %

N/A

CAD 0.05B
LIFE-B:CA Evolve Global Healthcare .. 5.03 % 0.00 %

+0.45 (+0.05%)

CAD 0.01B
XGES:LSE Xtrackers MSCI Genomic He.. 4.63 % 0.00 %

-0.24 (0.05%)

USD 3.51M
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.22 % 0.00 %

-0.03 (0.05%)

USD 0.15B
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.21 % 0.00 %

-0.22 (0.05%)

USD 3.51M
XDGI:XETRA Xtrackers MSCI Global SDG.. 3.51 % 0.00 %

-0.07 (0.05%)

USD 0.01B
RUD-U:CA RBC Quant U.S. Dividend L.. 3.28 % 0.00 %

N/A

N/A
RUD:CA RBC Quant US Dividend Lea.. 3.28 % 0.43 %

+0.26 (+0.05%)

CAD 0.48B
DHS:SW WisdomTree US Equity Inco.. 2.95 % 0.00 %

+0.02 (+0.05%)

N/A
DHSA:SW WisdomTree US Equity Inco.. 2.95 % 0.00 %

N/A

USD 0.04B
TDIV:SW VanEck Morningstar Develo.. 2.78 % 0.00 %

-0.01 (0.05%)

USD 0.64B
TDGB:LSE VanEck Morningstar Develo.. 2.70 % 0.00 %

-0.13 (0.05%)

USD 0.58B
TDIV:LSE VanEck Morningstar Develo.. 2.70 % 0.00 %

-0.23 (0.05%)

USD 0.64B
HEAL:CA 2.66 % 0.00 %

N/A

N/A
FHH:CA First Trust AlphaDEX US H.. 1.99 % 0.77 %

N/A

CAD 0.01B
FHH-F:CA First Trust AlphaDEX U.S... 1.99 % 0.00 %

N/A

CAD 0.01B
H41D:XETRA HSBC MSCI World Value ESG.. 1.91 % 0.00 %

-0.01 (0.05%)

USD 0.18B
FTLS First Trust Long/Short Eq.. 1.85 % 1.59 %

-0.46 (0.05%)

USD 1.13B
PUD.B:CA 1.82 % 0.66 %

N/A

N/A
UVDV 1.72 % 0.00 %

N/A

N/A
DSTL Distillate US Fundamental.. 1.68 % 0.00 %

-0.04 (0.05%)

USD 1.74B
JAVA JPMorgan Active Value ETF 1.53 % 0.00 %

-0.01 (0.05%)

USD 1.04B
UC82:LSE UBS(Lux)Fund Solutions .. 1.35 % 0.00 %

-0.25 (0.05%)

USD 0.07B
UC86:LSE UBS(Lux)Fund Solutions .. 1.35 % 0.00 %

-0.01 (0.05%)

USD 0.30B
SPXB ProShares S&P 500® Bond .. 1.32 % 0.15 %

N/A

USD 9.35M
FELV Fidelity Enhanced Large C.. 0.98 % 0.00 %

+0.02 (+0.05%)

USD 1.93B
UC98:LSE UBS(Lux)Fund Solutions .. 0.74 % 0.00 %

-4.50 (0.05%)

USD 0.18B
BSUS:LSE UBS(Lux)Fund Solutions .. 0.72 % 0.00 %

-4.00 (0.05%)

USD 0.16M
UC97:LSE UBS(Lux)Fund Solutions .. 0.72 % 0.00 %

-0.08 (0.05%)

USD 0.18B
UET0:F UBS (Lux) Fund Solutions .. 0.65 % 0.00 %

-0.08 (0.05%)

N/A
UET0:XETRA UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

-0.08 (0.05%)

USD 0.21B
CBSUST:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

-0.04 (0.05%)

USD 0.03B
CBSUS:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

-0.10 (0.05%)

USD 0.18B
CBSUSE:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

N/A

USD 0.24B
CBSUSH:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

N/A

USD 0.06B
QUIG:CA Mackenzie US Investment G.. 0.62 % 0.28 %

+0.15 (+0.05%)

CAD 0.48B
UC76:LSE UBS Barclays US Liquid Co.. 0.53 % 0.00 %

-0.06 (0.05%)

USD 0.08B
UC85:LSE UBS Barclays US Liquid Co.. 0.53 % 0.00 %

-5.50 (0.05%)

USD 0.06B
DEW WisdomTree Global High Di.. 0.00 % 0.58 %

+0.05 (+0.05%)

USD 0.11B
DHS WisdomTree U.S. High Divi.. 0.00 % 0.38 %

+0.04 (+0.05%)

USD 1.08B
GBF iShares Government/Credit.. 0.00 % 0.20 %

-0.27 (0.05%)

USD 0.24B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

-0.40 (0.05%)

USD 0.69B
JHMH 0.00 % 0.46 %

N/A

N/A
QLTA iShares Aaa - A Rated Cor.. 0.00 % 0.15 %

-0.13 (0.05%)

USD 1.02B
NUBD Nuveen ESG U.S. Aggregate.. 0.00 % 0.20 %

-0.06 (0.05%)

USD 0.34B
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

-0.06 (0.05%)

USD 0.02B
HONR 0.00 % 0.65 %

N/A

N/A
HUL-U:CA 0.00 % 0.00 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

+0.04 (+0.05%)

USD 1.09M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.04 (+0.05%)

USD 1.09M
SICK 0.00 % 0.95 %

N/A

N/A
UXM.B:CA 0.00 % 0.67 %

N/A

N/A
HUL:CA 0.00 % 2.20 %

N/A

N/A
BVAL 0.00 % 0.65 %

N/A

N/A
DHS:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

-1.65 (0.05%)

USD 0.03B
DHSA:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

-0.08 (0.05%)

USD 0.04B
DHSD:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

-0.07 (0.05%)

USD 0.03B
DHSG:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

-6.25 (0.05%)

USD 0.75M
DHSP:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

-5.50 (0.05%)

USD 0.04B
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-22.50 (0.05%)

USD 0.01B
UC84:LSE UBS Barclays US Liquid Co.. 0.00 % 0.00 %

-4.25 (0.05%)

USD 0.08B
USMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

+0.33 (+0.05%)

USD 0.01B
XSD2:LSE db x-trackers ShortDAX x2.. 0.00 % 0.00 %

+0.62 (+0.05%)

USD 0.13B
MVUS:PA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

N/A

USD 0.01B
SPMV:PA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

N/A

USD 7.79M
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.00 %

+0.20 (+0.05%)

N/A
VDIV:F VanEck Vectors ETFs N.V... 0.00 % 0.00 %

-0.17 (0.05%)

USD 0.64B
WTD9:F WisdomTree US Equity Inco.. 0.00 % 0.00 %

+0.02 (+0.05%)

USD 0.06B
WTDY:F WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

+0.05 (+0.05%)

USD 0.64M
WTEU:F WisdomTree US Equity Inco.. 0.00 % 0.00 %

-0.04 (0.05%)

USD 0.11B
OSX2:XETRA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

+0.15 (+0.05%)

USD 0.12B
VDIV:XETRA VanEck Morningstar Develo.. 0.00 % 0.00 %

-0.11 (0.05%)

USD 0.64B
VMUS:XETRA 0.00 % 0.00 %

N/A

N/A
WTD9:XETRA WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

-0.05 (0.05%)

USD 0.05B
WTDY:XETRA WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

-0.07 (0.05%)

USD 0.85M
WTEU:XETRA WisdomTree US Equity Inco.. 0.00 % 0.00 %

-0.04 (0.05%)

USD 0.11B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
HART IQ Healthy Hearts ETF 0.00 % 0.00 %

+0.02 (+0.05%)

USD 8.64M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.48% 15% F 3% F
Dividend Return 0.79% 50% F 68% D+
Total Return -4.69% 15% F 3% F
Trailing 12 Months  
Capital Gain -18.01% 26% F 28% F
Dividend Return 2.69% 50% F 50% F
Total Return -15.32% 26% F 28% F
Trailing 5 Years  
Capital Gain -10.35% 53% F 37% F
Dividend Return 13.96% 53% F 49% F
Total Return 3.61% 53% F 34% F
Average Annual (5 Year Horizon)  
Capital Gain 3.78% 68% D+ 61% D-
Dividend Return 6.38% 63% D 56% F
Total Return 2.60% 53% F 51% F
Risk Return Profile  
Volatility (Standard Deviation) 17.84% 63% D 41% F
Risk Adjusted Return 35.74% 58% F 45% F
Market Capitalization 93.95B 69% C- 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 55.20 23% 9%
Price/Book Ratio 6.51 16% 10%
Price / Cash Flow Ratio 4.36 24% 26%
Price/Free Cash Flow Ratio 21.55 31% 25%
Management Effectiveness  
Return on Equity 11.34% 69% 61%
Return on Invested Capital 21.86% 85% 85%
Return on Assets 4.31% 65% 63%
Debt to Equity Ratio 60.50% 52% 56%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.